News
Biotech firms name new CEOs, leadership after BIO
8+ hour, 55+ min ago (443+ words) Symeres and Axxam also join the fray, choosing a new CSO to lead their scientific strategy. The biotech industry continues to push ahead full force after last week's BIO International Convention, with companies shaking up their leadership and assigning new…...
Lehigh Valley Snags $5 Million Shot To Fast'Track Locals Into Lilly
9+ hour, 59+ min ago (420+ words) Mega'Plant Jobs Hoodline Explore Our Cities & Metro Areas (A-Z) Lehigh Valley Snags $5 Million Shot To Fast'Track Locals Into Lilly Mega'Plant Jobs The Lehigh Valley just landed a serious workforce windfall. Pennsylvania is giving Lehigh Carbon Community College a $5 million grant…...
Takeda deal lets us scale our capabilities: Insilico Medicine CEO
1+ hour, 22+ min ago (80+ words) Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery. He breaks down the deal's structure, roughly sixty million upfront…...
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
10+ hour, 7+ min ago (585+ words) Novartis NVS obtained approval from the European Commission (EC) for Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron…...
Takeda Partners with Insilico Medicine in Up to $600 M AI Drug Discovery Collaboration
4+ hour, 36+ min ago (177+ words) 03 July 2026 | Friday | News Insilico Medicine ("Insilico" HKEX: 3696), a leader in clinical-stage generative AI for drug discovery, announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma. AI, to advance drug candidates across the company's therapeutic areas....
Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies
4+ hour, 43+ min ago (430+ words) Bio Pharma APAC - Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies 03 July 2026 | Friday | News Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announced a strategic collaboration with…...
Ribo and Madrigal Achieve First si RNA Candidate Milestone for MASH Therapy
4+ hour, 36+ min ago (339+ words) Bio Pharma APAC - Ribo and Madrigal Achieve First si RNA Candidate Milestone for MASH Therapy 03 July 2026 | Friday | News Suzhou Ribo Life Science Co. , Ltd. (06938. HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal…...
Up and down the ladder: The latest comings and goings
9+ hour, 3+ min ago (118+ words) And here is our regular feature in which we highlight a different person each week. This time around, we note that'Protillion Biosciences hired Robert Hollingsworth as chief scientific officer. Previously, he held the same role at Shoreline Therapeutics and, before…...
Neuro Thera Labs Announces Upsize to Private Placement
6+ hour, 48+ min ago (561+ words) The Newswire Neuro Thera Labs Announces Upsize to Private Placement Toronto, ON " July 2, 2026 - The Newswire " Neuro Thera Labs Inc. (the "Company" or "Neuro Thera") (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of Sci Sparc Ltd. (Nasdaq: SPRC),…...
Odyssey AI raises US$310m, valued at NZ$2. 5b
6+ hour, 42+ min ago (541+ words) Auckland-educated founder Jeff Hawke has closed a US$310 million (NZ$529m) Series B round for his AI company Odyssey, valuing the business at US$1. 45 billion (NZ$2. 5 billion). The round was led by US firm Natural Capital, with Amazon, AMD Ventures, the…...